|
Supplemental report submitted to include additional information received and completion of the engineering evaluation.Updated d4 and h4.The device was returned for evaluation and an engineering evaluation was performed.The returned device was visually examined, and the following was observed: the liner was fully expanded.The distal tip was torn radially near distal edge of liner.All score lines were present with stretching noted on the hdpe and soft tip a review of edwards lifesciences risk management documentation was performed for this case.The reported event is an anticipated risk of the transcatheter heart valve procedure, additional assessment of the failure mode is not required at this time.The complaint sheath distal tip torn was confirmed per evaluation of the returned device.However, no manufacturing nonconformance was identified during evaluation.Review of the dhr and lot history did not provide any indication that a manufacturing non-conformance would have contributed to the complaints.A review of manufacturing mitigations supports that the sheath has proper inspections in place to detect issues related to the complaint events.A review of ifu/training materials revealed no deficiencies.Furthermore, no abnormalities were noted during device unpacking or preparation.Per the complaint description, ''edwards received notification through the alliance clinical trial that following completion of the case, it was noted that the distal tip of 914esa esheath was torn.There was no report of resistance between the valve/delivery system and the esheath''.Per evaluation of the returned device, the sheath distal tip was observed to be torn radially along the distal edge of the liner.The failure mode is characteristic of sheath tip tear events as described in a product risk assessment (pra).While a definitive root cause was unable to be determined, previous investigation indicated that the tear is attributed to improper tip expansion, resulting in interference between the valve and sheath tip.As such, it is possible that improper tip expansion contributed to the experienced delivery system advancement resistance at the sheath distal tip and the distal tip tear.Additionally, 3mensio imagery was also provided and shows the presence of vessel tortuosity, calcification undersized vessel dimensions.Per the training manual, ''push force can vary due to angle of access and insertion, thv size, vessel diameter, tortuosity and degree of calcification''.Calcification can create a constrained effect on the sheath leading to sub-optimal conditions for distal tip expansion.Calcification and tortuosity can also lead to non-coaxial alignment between the crimped valve and the sheath, which may lead to the valve struts to catch onto the sheath distal tip, tearing the tip in the process of advancement.'' as such, the failure mode may be related to improper expansion of the sheath tip during thv advancement and/or patient factors (tortuosity, calcification) may have contributed to the complaint events.However, a definitive root cause is unable to be determined.A product risk assessment (pra) was previously initiated to document investigation and assess associated risks for the issue and a capa captures process improvement activities.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.
|